phentermine has been researched along with Metabolic Diseases in 2 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 9.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 5.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Phentermine is a noradrenergic sympathomimetic amine approved for short-term treatment of obesity." | 4.86 | Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. ( Bays, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bays, H | 1 |
| Garvey, WT | 1 |
| Ryan, DH | 1 |
| Look, M | 1 |
| Gadde, KM | 1 |
| Allison, DB | 1 |
| Peterson, CA | 1 |
| Schwiers, M | 1 |
| Day, WW | 1 |
| Bowden, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.[NCT00796367] | Phase 3 | 676 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00796367)
Timeframe: From baseline to end of treatment
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| VI-0521 Mid | -9.32 |
| VI-0521 Top | -10.5 |
(NCT00796367)
Timeframe: Baseline to End of Treatment
| Intervention | percent participants (Number) |
|---|---|
| Placebo | 30 |
| VI-0521 Mid | 75.2 |
| VI-0521 Top | 79.3 |
1 review available for phentermine and Metabolic Diseases
| Article | Year |
|---|---|
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Topics: Adipose Tissue; Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; | 2010 |
1 trial available for phentermine and Metabolic Diseases
| Article | Year |
|---|---|
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; | 2012 |